Transferosomes as Drug Delivery Systems: Design Principles, Deformability, and Translational Challenges
- 1Nova Southeastern University
- 2Ana G. Mendez University System
Abstract
Transferosomes are liposome-derived ultradeformable vesicles designed to improve drug delivery across restrictive biological barriers, particularly in non-invasive administration routes. Their structure is based on phospholipid bilayers modified with edge activators, usually surfactants or bile salts, which increase membrane flexibility while preserving vesicular organization. This balance between deformability and stability distinguishes transferosomes from conventional liposomes and has supported their use in dermal, transdermal, ocular, nasal, buccal, and other mucosal delivery systems. However, despite extensive experimental interest, the field remains limited by inconsistent terminology, heterogeneous formulation strategies, non-harmonized deformability assays, and incomplete translation from laboratory formulations to clinically relevant products. This review critically examines transferosomes from a formulation-development perspective, focusing on the relationship between lipid composition, edge-activator selection, vesicle properties, deformability, drug release, and biological performance. Particular attention is given to critical quality attributes, analytical characterization, mechanistic interpretations of barrier interaction, and the unresolved debate between intact vesicle penetration, drug-release-dominated delivery, and barrier perturbation. Transferosomes are also positioned in comparison with conventional liposomes, ethosomes, and transethosomes. Finally, the review identifies key unmet needs related to standardization, reproducibility, scalability, storage stability, and regulatory uncertainty. By integrating formulation design with mechanistic and translational analysis, this review aims to clarify when transferosomes offer a genuine delivery advantage and which parameters must be controlled to support their further pharmaceutical development.
Related
- Ethosomal drug delivery systems for skin cancer: Mechanistic insights, formulation strategies, and translational challenges.
- Polydeoxyribonucleotide (PDRN) in Osteoarthritis: Immunomodulatory and Matrix-Supportive Potential, A2A Receptor-Associated Mechanisms, and Translational Challenges
- Cellular immunotherapy for lung cancer: current clinical evidence, translational challenges, and future perspectives: a narrative review
- Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Genome Editing in Inherited Cardiovascular Diseases: Therapeutic Advances, Emerging Editing Platforms, and Translational Challenges
- Microwave-induced in situ amorphization: mechanistic basis, formulation principles, and translational perspective
BibTeX
@article{nieves2026transferosomes,
title = {{Transferosomes as Drug Delivery Systems: Design Principles, Deformability, and Translational Challenges}},
author = {Enrique A. Nieves and María C. Cotto and Francisco Márquez},
journal = {Pharmaceuticals},
year = {2026},
month = jun,
doi = {10.3390/ph19060956},
url = {https://doi.org/10.3390/ph19060956},
note = {CC BY},
}
RIS
TY - JOUR
TI - Transferosomes as Drug Delivery Systems: Design Principles, Deformability, and Translational Challenges
AU - Enrique A. Nieves
AU - María C. Cotto
AU - Francisco Márquez
PY - 2026
DA - 2026/06/19
JO - Pharmaceuticals
DO - 10.3390/ph19060956
UR - https://doi.org/10.3390/ph19060956
AB - Transferosomes are liposome-derived ultradeformable vesicles designed to improve drug delivery across restrictive biological barriers, particularly in non-invasive administration routes. Their structure is based on phospholipid bilayers modified with edge activators, usually surfactants or bile salts, which increase membrane flexibility while preserving vesicular organization. This balance between deformability and stability distinguishes transferosomes from conventional liposomes and has supported their use in dermal, transdermal, ocular, nasal, buccal, and other mucosal delivery systems. However, despite extensive experimental interest, the field remains limited by inconsistent terminology, heterogeneous formulation strategies, non-harmonized deformability assays, and incomplete translation from laboratory formulations to clinically relevant products. This review critically examines transferosomes from a formulation-development perspective, focusing on the relationship between lipid composition, edge-activator selection, vesicle properties, deformability, drug release, and biological performance. Particular attention is given to critical quality attributes, analytical characterization, mechanistic interpretations of barrier interaction, and the unresolved debate between intact vesicle penetration, drug-release-dominated delivery, and barrier perturbation. Transferosomes are also positioned in comparison with conventional liposomes, ethosomes, and transethosomes. Finally, the review identifies key unmet needs related to standardization, reproducibility, scalability, storage stability, and regulatory uncertainty. By integrating formulation design with mechanistic and translational analysis, this review aims to clarify when transferosomes offer a genuine delivery advantage and which parameters must be controlled to support their further pharmaceutical development.
SN - 1424-8247
ER -